Technical Analysis for IMV - IMV Inc

Grade Last Price % Change Price Change
grade D 2.88 -3.68% -0.1100
IMV closed down 3.68 percent on Monday, September 9, 2019, on 2.26 times normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical IMV trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
New 52 Week Closing Low Bearish -3.68%
New 52 Week Low Weakness -3.68%
Gapped Down Weakness -3.68%
Gapped Up Strength -49.21%
Outside Day Range Expansion -47.73%
Narrow Range Bar Range Contraction -48.19%
NR7 Range Contraction -48.19%

Older signals for IMV ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is based in Dartmouth, Canada.
Medicine Medical Specialties Cancer Clinical Medicine Immunotherapy Cancer Immunotherapy Vaccines Ovarian Cancer Malaria Cancer Therapy Treating Cancer Hpv Lymphoma Lead Cancer Therapies For Cancer
Is IMV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.0
52 Week Low 2.59
Average Volume 3,361
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 5.0069
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.3600
Resistance 3 (R3) 3.3167 3.1133 3.2800
Resistance 2 (R2) 3.1133 2.9911 3.1350 3.2533
Resistance 1 (R1) 2.9967 2.9156 3.0550 3.0400 3.2267
Pivot Point 2.7933 2.7933 2.8225 2.8150 2.7933
Support 1 (S1) 2.6767 2.6711 2.7350 2.7200 2.5333
Support 2 (S2) 2.4733 2.5956 2.4950 2.5067
Support 3 (S3) 2.3567 2.4733 2.4800
Support 4 (S4) 2.4000